Effect of human activated NRAS on replication of delNS1 H5N1 influenza virus in MDCK cells
© Zhu et al; licensee BioMed Central Ltd. 2011
Received: 20 September 2010
Accepted: 19 May 2011
Published: 19 May 2011
RAS, coded by ras proto-oncogenes, played an important role in signal transmission to regulate cell growth and differentiation. Host activation of RAS was significant for IFN-sensitive vaccinia virus (delE3L) or attenuate influenza virus in unallowable cells.
Huamn NRAS gene was activated by mutating in codon 61. Then the activation of NRAS was detected by western blot in MDCK cells. The delNS1 H5N1 influenza virus with deletion of NS1 eIF4GI binding domain was weak multiplication in MDCK cells. And the replication of delNS1 virus and expression of IFN-beta and IRF-3 were detected by Real-time PCR in MDCK cells infected with delNS1 virus. It was found that the delNS1 virus had a significant increase in MDCK cells when the NRAS was activated, and yet, expression of IRF-3 and IFN-beta were restrained.
The study demonstrated that activated NRAS played an important part for delNS1 virus replication in MDCK cells. Activated NRAS might be down-regulating the expression of antiviral cellular factors in delNS1 virus infected cells.
The RAS family (NRAS, KRAS and HRAS) were members of the superfamily of small GTP/GDP-binding protein. They were known for their diverse intracellular signaling function in various organisms, such as controlling of cell proliferation, growth and apoptosis. Activating mutation in RAS occurred in up to 30% of human cancers. There were three ways to activate RAS protein: point mutation in ras gene, great amount expression of RAS and gene insertion or dislocation [1–3]. It was often found point mutations of codons 12, 13 or 61 in ras gene [4, 5]. Constitutively active RAS, like the V12 mutation and V61 mutation, was predominantly binding with GTP, because of lower intrinsic GTPase activity and its resistance to the GTPase-stimulating activity of RASGAPs [6, 7]. Activated RAS displayed oncogenic potential, being assistances of several downstream effectors including Raf, phosphatidylinositol 3-kinase and etc [8, 9]. In RAS-transformed cells, activated RAS protein rendered cells permissive to defected virus, like delNS1 influenza virus (an influenza virus lacking the NS1 open reading frame), by a mechanism that involved induction of cellular inhibitor of PKR .
The nonstructural protein (NS1) of influenza virus was an important regulatory protein in virus replication and multiplication especially preventing host antivirus action. Previous studies suggested that binding of dsRNA by the NS1 protein blocked the action of the interferon (IFN)-inducible dsRNA-dependent protein kinase (PKR) [11, 12]. The eIF4GI binding domain-truncated influenza virus did not efficiently replicate and was impaired in its ability to inhibit IFN production in vitro .
Previously, the delNS1 influenza virus (an influenza virus lacking the NS1 open reading frame) selectively replicated in the NRAS-expressing melanomas and had tumor-ablative potentials . They reasoned that an activated ras-signaling pathway and inactivated PKR might allow replication of the delNS1 virus. In present study, NRAS was activated through point mutation in codon 61 (named NRAS (K61)). The replication of delNS1 virus was higher lever in MDCK transfected NRAS (K61). But the expression of IFN was inhibited in cells which had activated NRAS and virus incubating. Therefore, NRAS (K61) transient expressing in MDCK cells might make up for the deficiency of delNS1 influenza virus through inhibiting IFN effect.
Cell culture and Virus
A549 cells were maintained in F12 medium (SIGMA) supplemented with 10% FBS. And Madin-Darby canine kidney (MDCK) cells were in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) with 10% FBS. DelNS1 influenza virus (H5N1) with the deletion of NS1 eIF4GI binding domain was described previously .
Construction of mutated plasmids
The NRAS ORF gene was amplified from A549 cells. And then the NRAS gene mutated in codons 61 (Q-K) by point mutation. PcDNA3.1 (+)-NRAS (K61) was made by inserting the NRAS.
Plasmid transfections and virus infection
Liposomes (Invitrogen) were mixed with 3 μg DNA. And then, the transfection of MDCK cells was followed the manufacturer's instruction. After 12 h of transfection, MDCK in 6-well plates were incubated with delNS1 virus at a multiplicity of infection (MOI) of 0.1 in DMEM with FBS free at 37°C. One hour later, virus-containing solutions were removed by washing the cells twice with PBS. Infected cells were incubated in maintain medium with 2% FBS in a CO2 incubator at 37°C. Cell Supernatants and cells were harvested at 12 h, 24 h and 36 h after infection for western blot analysis and real time PCR. Experiments with delNS1 H5N1 virus were conducted in biosafety level 3+ containment facility.
After 36 h of transfected with NRAS (K61), cells' apoptosis was detected by cell death detection kit (Roche) following the manufacturer's instruction.
Western blot analysis
Cells were harvested at 36 hours after transfection of NRAS (K61). Whole cells were lysed using RIPA buffer containing the cocktail of protease inhibitors (Roche Molecular Biology). Total protein was loaded on to SDS-PAGE and transferred on to nitrocellulose paper. The blot was incubated with the NRAS-specific monoclonal antibody F155 (Santa Cruz Biotechnology) followed by matching horseradish peroxidase-conjugated secondary antibody. Protein bands were visualized by enhanced chemiluminescence (Thermo).
Real-time quantitative PCR for IFN-beta, IRF-3 and delNS1 virus production
To quantify the expressing levels of IFN-beta, IRF-3 and the replication of delNS1 influenza virus produced in NRAS (K61) activated cells infected with the delNS1 influenza viruses, a real-time quantitative PCR assay was used for IFN-beta, IRF-3 and NP. Total RNA was extracted from the MDCK cells with the RNA isolation kit (Qiagen), following the manufacturer's instruction. Total RNA (1 μg) was used for the synthesis of the first strand of cDNA. Reverse transcription (RT) was then carried out using the AMV Reverse Transcriptase XL kit (Takara). Real-time quantitative polymerase chain reaction (PCR) was conducted with 1 μl cDNA in a total volume of 25 μl with the iQ SYBR Green supermix (Bio-Rad), following the manufacturer's instruction. Relative expression values were normalized using a beta-actin internal control. The following oligonucleotide primer pairs were examined: beta-actin forward CGAGACATTCAACACCCCAAC, beta-actin reverse AGCCAGGTCCAGACGCAAG, IFN-beta forward CGCCGCAAGGACAGGATA, IFN-beta reverse ACGGGAGGTTCA-CAAGAAGGTT, IRF-3 forward GTTGGTAACAGACAAGACCGTGAT, IRF-3 reverse GAGTGTCGGCTTCCTTTGATG, NP forward TATTCGTCTCAGGGAGC-AAAAGCAGGGTA, and NP reverse ATATCGTCTCGTATTAGTAGAAACAAG-GGTATTTTT.
Overexpression of mutated NRAS (K61) in MDCK cells
IFN-beta and IRF-3 gene expression and delNS1 virus multiplication in MDCK cells
RAS was a member of a small GTPase superfamily, which could regulate a series of cell proliferation and apoptosis. In the present study, it was found that transient expression of oncogenic NRAS (K61) in MDCK cells influenced cell morphology and cell-cell contacts, leading to the production of comet cell. However, the typical apoptosis of the cells was not observed. It might be the way that constitutive activation of RAS resisted cell death with the change of cell morphology. In mouse cells, a transient increase in the cytoplasmic level of oncogenic H-Ras (H-Ras (V12)) led to disintegrate of E-cadherin complexes and activated of beta-catenin-dependent transcription in gene reporter assays .
RAS was activated in host, favorably for variety viral infection. In the HIV-1 model, downstream signaling pathways of RAS activation was beneficial to viral replication . Similarly, some other viruses also interacted with RAS, such as influenza virus (delNS1 strain), hepatitis B virus, reovirus, vesicular stomatitis virus (VSV) and adenovirus (VAI mutant) [10, 16–19]. Activated RAS was participated in different signaling pathway and exercised multiple functions in various virus proliferations. In the activated form of RAS, it was shown an increase of the HBV X protein. In addition, activation of the RAS signal transduction pathway could enhance the central transcription factor, TBP, and the induce of RNA pol III-dependent gene activity in Hepatitis B Virus infected cells, which increased the viral replication . Cells with an activated RAS/RAF/MEK signaling cascade allowed propagation of viruses in the presence of IFN. Vesicular stomatitis virus (VSV) or an IFN-sensitive vaccinia virus (delE3L) infected RAS-transformed (RasV12) cells in the presence of alpha interferon, both of which were found to similarly flourish in cells regardless of the presence of IFN . In this study, it was observed prominent increase of delNS1 virus in the cell of activated NRAS (K61), which meant effective replication of delNS1 virus.
In the present study, the delNS1 H5N1 influenza viruses with the deletion of eIF4GI binding domain displayed attenuated virulence in MDCK cells. In addition, this delNS1 H5N1 strain could stimulate strong response of IFN. DelNS1 virus lacking eIF4GI binding domain was weak multiplication in MDCK cells because of omnipresent dsRNA-dependent protein kinase (PKR) inducing antivirus action or unable preferential translation viral mRNA [21, 22]. Recent studies were shown that the NS1 protein of influenza A virus was a major force to antagonize activation of PKR and the expression of early defense genes, including IFN-beta [11, 12, 23, 24]. IRF-3, as a transcription factor required for the induction of IFN-beta, also could be inhibited by NS1 protein [23, 25–28].
In current study, growth of delNS1 virus was dependent on expression of NRAS (K61) in MDCK cells. And it was shown that activated RAS down-regulated IFN-induced antiviral responses. It was demonstrated that activated RAS had been entangled in the negative regulation of the IFN response. Previous study showed that the active K-RAS restrained the IFN-gamma-activated sequence-mediated transcription of IFN-gamma in human cancer cells . And viral oncogene (v-RAS) was transfected in BALB/c-3T3 cells leading to inhibition of induction of MHC I by IFN-alpha . Some other studies also reported that the suppression of the IFN response by activated RAS could be a common mechanism which was exploited by some oncolytic viruses. This effect was mediated at least in part by the ability of the RAS/ERK signaling pathway to inhibit activation of IRF-3 . IRF-1, initially described as a transactivator of the IFN-beta gene, was deregulated in RAS-transformed mouse fibroblasts (RS485) [31–33]. The cellular activity of the RAS/MEK pathway might influence cellular susceptibility to IFN and be the making of host susceptibility to virus .
In conclusion, this study demonstrated that activated RAS could help defective influenza virus propagation. It is speculated that constitutive activation of RAS inhibited IFN antivirus defenses and afforded more favorable environment for replication of delNS1 influenza virus. The virus-infected RAS activated cells were affected by the IFN in a complicated way, suggesting that RAS played a significant role in virus infection, preserving the cells, cell transformation and so on. The mode of action of RAS needs further research.
This study was supported by China National Basic Research Program (China "973" Program 2011CB505004 & 2010CB534002), National Natural Science Foundation of China (NO. 31072154 & 30800832) and National Transgenic Major Program (2009ZX08009-141B).
- Kobayashi Y, Kawaoi A, Katoh R: Mutation of ras oncogene in di-isopropanolnitrosamine-induced rat thyroid carcinogenesis. Virchows Arch 2002, 441: 289-295. 10.1007/s00428-002-0608-yView ArticlePubMedGoogle Scholar
- Bos JL: ras oncogenes in human cancer: a review. Cancer Res 1989, 49: 4682-4689.PubMedGoogle Scholar
- Colicelli J: Human RAS superfamily proteins and related GTPases. Sci STKE 2004, 2004: RE13. 10.1126/stke.2502004re13PubMed CentralPubMedGoogle Scholar
- Scheele JS, Ripple D, Lubbert M: The role of ras and other low molecular weight guanine nucleotide (GTP)-binding proteins during hematopoietic cell differentiation. Cell Mol Life Sci 2000, 57: 1950-1963. 10.1007/PL00000675View ArticlePubMedGoogle Scholar
- Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93: 1062-1074. 10.1093/jnci/93.14.1062View ArticlePubMedGoogle Scholar
- Krengel U, Schlichting I, Scherer A, Schumann R, Frech M, John J, Kabsch W, Pai EF, Wittinghofer A: Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 1990, 62: 539-548. 10.1016/0092-8674(90)90018-AView ArticlePubMedGoogle Scholar
- Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A: The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997, 277: 333-338. 10.1126/science.277.5324.333View ArticlePubMedGoogle Scholar
- Wasylyk B, Hagman J, Gutierrez-Hartmann A: Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 1998, 23: 213-216. 10.1016/S0968-0004(98)01211-0View ArticlePubMedGoogle Scholar
- Downward J: Ras signalling and apoptosis. Curr Opin Genet Dev 1998, 8: 49-54. 10.1016/S0959-437X(98)80061-0View ArticlePubMedGoogle Scholar
- Bergmann M, Romirer I, Sachet M, Fleischhacker R, Garcia-Sastre A, Palese P, Wolff K, Pehamberger H, Jakesz R, Muster T: A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res 2001, 61: 8188-8193.PubMedGoogle Scholar
- Bergmann M, Garcia-Sastre A, Carnero E, Pehamberger H, Wolff K, Palese P, Muster T: Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J Virol 2000, 74: 6203-6206. 10.1128/JVI.74.13.6203-6206.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Hatada E, Saito S, Fukuda R: Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. J Virol 1999, 73: 2425-2433.PubMed CentralPubMedGoogle Scholar
- Zhou HB, Zhu JP, Tu JG, Zou W: Effect on Virulence and Pathogenicity of H5N1 Influenza A Virus through Truncations of NS1 eIF4GI Binding Domain. J Infect Dis 2010, 202: 1338-1346. 10.1086/656536View ArticlePubMedGoogle Scholar
- Espada J, Galaz S, Sanz-Rodriguez F, Blazquez-Castro A, Stockert JC, Bagazgoitia L, Jaen P, Gonzalez S, Cano A, Juarranz A: Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytes. J Cell Physiol 2009, 219: 84-93. 10.1002/jcp.21652View ArticlePubMedGoogle Scholar
- Jacque JM, Mann A, Enslen H, Sharova N, Brichacek B, Davis RJ, Stevenson M: Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. Embo J 1998, 17: 2607-2618. 10.1093/emboj/17.9.2607PubMed CentralView ArticlePubMedGoogle Scholar
- Wang HD, Trivedi A, Johnson DL: Hepatitis B virus X protein induces RNA polymerase III-dependent gene transcription and increases cellular TATA-binding protein by activating the Ras signaling pathway. Mol Cell Biol 1997, 17: 6838-6846.PubMed CentralView ArticlePubMedGoogle Scholar
- Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW: Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004, 101: 11099-11104. 10.1073/pnas.0404310101PubMed CentralView ArticlePubMedGoogle Scholar
- Noser JA, Mael AA, Sakuma R, Ohmine S, Marcato P, Lee PW, Ikeda Y: The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 2007, 15: 1531-1536. 10.1038/sj.mt.6300193View ArticlePubMedGoogle Scholar
- Cascallo M, Capella G, Mazo A, Alemany R: Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003, 63: 5544-5550.PubMedGoogle Scholar
- Battcock SM, Collier TW, Zu D, Hirasawa K: Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 2006, 80: 4422-4430. 10.1128/JVI.80.9.4422-4430.2006PubMed CentralView ArticlePubMedGoogle Scholar
- Aragon T, de la Luna S, Novoa I, Carrasco L, Ortin J, Nieto A: Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus. Mol Cell Biol 2000, 20: 6259-6268. 10.1128/MCB.20.17.6259-6268.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Burgui I, Aragon T, Ortin J, Nieto A: PABP1 and eIF4GI associate with influenza virus NS1 protein in viral mRNA translation initiation complexes. J Gen Virol 2003, 84: 3263-3274. 10.1099/vir.0.19487-0View ArticlePubMedGoogle Scholar
- Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, Garcia-Sastre A: Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol 2000, 74: 7989-7996. 10.1128/JVI.74.17.7989-7996.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Geiss GK, Salvatore M, Tumpey TM, Carter VS, Wang X, Basler CF, Taubenberger JK, Bumgarner RE, Palese P, Katze MG, Garcia-Sastre A: Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci USA 2002, 99: 10736-10741. 10.1073/pnas.112338099PubMed CentralView ArticlePubMedGoogle Scholar
- Lin R, Heylbroeck C, Pitha PM, Hiscott J: Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 1998, 18: 2986-2996.PubMed CentralView ArticlePubMedGoogle Scholar
- Pitha PM, Au WC, Lowther W, Juang YT, Schafer SL, Burysek L, Hiscott J, Moore PA: Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth. Biochimie 1998, 80: 651-658. 10.1016/S0300-9084(99)80018-2View ArticlePubMedGoogle Scholar
- Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T: Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell 1998, 1: 507-518. 10.1016/S1097-2765(00)80051-9View ArticlePubMedGoogle Scholar
- Donelan NR, Dauber B, Wang X, Basler CF, Wolff T, Garcia-Sastre A: The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J Virol 2004, 78: 11574-11582. 10.1128/JVI.78.21.11574-11582.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Klampfer L, Huang J, Corner G, Mariadason J, Arango D, Sasazuki T, Shirasawa S, Augenlicht L: Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. J Biol Chem 2003, 278: 46278-46287. 10.1074/jbc.M304721200View ArticlePubMedGoogle Scholar
- Offermann MK, Faller DV: Effect of cellular density and viral oncogenes on the major histocompatibility complex class I antigen response to gamma-interferon in BALB-c/3T3 cells. Cancer Res 1990, 50: 601-605.PubMedGoogle Scholar
- Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi T: Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988, 54: 903-913. 10.1016/S0092-8674(88)91307-4View ArticlePubMedGoogle Scholar
- Gira AK, Casper KA, Otto KB, Naik SM, Caughman SW, Swerlick RA: Induction of interferon regulatory factor 1 expression in human dermal endothelial cells by interferon-gamma and tumor necrosis factor-alpha is transcriptionally regulated and requires iron. J Invest Dermatol 2003, 121: 1191-1196. 10.1046/j.1523-1747.2003.12535.xView ArticlePubMedGoogle Scholar
- Attard FA, Contente S, Yeh TJ, Buchhagen DL, Friedman RM: Mechanisms of deregulation of IFN regulatory factor-1 in ras-transformed fibroblasts. J Interferon Cytokine Res 2005, 25: 418-423. 10.1089/jir.2005.25.418View ArticlePubMedGoogle Scholar
- Christian SL, Collier TW, Zu D, Licursi M, Hough CM, Hirasawa K: Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels. J Virol 2009, 83: 6717-6726. 10.1128/JVI.02213-08PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.